Search | Page 12 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: What do hospitalists need to know?

    ... agents such as azacitidine (Vidaza®) and decitabine (Dacogen®), intensive chemotherapy, and stem cell transplantation.  Patients tend to tolerate azacitidine and decitabine fairly well.  These agents appear to restore normal cell production ...

    Research Review last updated 05/02/2016 - 9:21am.

  2. Nursing Education Modules on MDS Disease Management and Patient Education

    ... options for high-risk MDS – azacitidine , decitabine , allo-HSCT, clinical trials MDS treatment goals – ...

    Page last updated 04/27/2015 - 2:44pm.

  3. Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

    ... treatment with demethylating agents (azacytidine or decitabine , lenalidomide , etc) ALLOWED. Cohort B: Patients who ...

    Clinical Trial last updated 06/13/2016 - 3:31pm.

  4. FAQs

    ... currently include lenalidomide (Revlimid), decitabine (Dacogen) and azacitidine (Vidaza). Chemotherapy ... These include lenalidomide (Revlimid®) decitabine (Dacogen®) and azacitidine (Vidaza®). Learn more about ...

    Topic section last updated 03/02/2016 - 11:42am.

  5. Clinical Trials Report for January 2015

    ... Study Coordinator Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) ... research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing ...

    Page last updated 12/30/2014 - 10:45am.

  6. Clinical Trials Report for March 2015

    ... Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) ... research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard ...

    Page last updated 03/02/2015 - 10:06am.

  7. Clinical Trials Report for December 2014

    ... Study Coordinator Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) ... research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing ...

    Page last updated 11/25/2014 - 3:33pm.

  8. Clinical Trials Report for April 2015

    ... identifier: NCT02363491 Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) ... research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard ...

    Page last updated 03/30/2015 - 11:40am.

  9. Clinical Trials Report for January 2016

    ... Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS) This 2-stage, ...

    Page last updated 01/07/2016 - 10:57am.

  10. A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

    ... Associated Drug(s):  Decitabine Phase:  ... administered orally and continuously for 28 days. Drug: Decitabine Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days Drug: ...

    Clinical Trial last updated 04/27/2016 - 9:27am.